Astellas v. Deva Holdings: Mirabegron Patent Dispute Settled in 208 Days
Astellas Pharma filed suit against Deva Holding A/S in Delaware District Court asserting four patents covering Myrbetriq® mirabegron extended-release tablets. The parties reached a settlement and license agreement, resulting in dismissal without prejudice after 208 days — a resolution pace typical of Hatch-Waxman ANDA litigation settlements.
Hatch-Waxman Mirabegron Dispute Ends in Licensed Settlement
On 28 February 2025, Astellas Pharma, Inc., Astellas Ireland Co., Ltd., and Astellas Pharma Global Development, Inc. (collectively, Astellas) filed an infringement action in the Delaware District Court against Deva Holding A/S, asserting four US patents — US10842780B2, US11707451B2, US12059409B1, and US12097189B1 — all directed to mirabegron extended-release oral tablet formulations marketed by Astellas as Myrbetriq® in 25 mg and 50 mg doses. Deva’s equivalent generic product — 25 mg and 50 mg mirabegron extended-release tablets — triggered the Paragraph IV certification challenge characteristic of Hatch-Waxman litigation.
The case closed on 24 September 2025, 208 days after filing, when the parties filed a joint stipulation of dismissal without prejudice pursuant to a Settlement and License Agreement. Consistent with the requirements of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA), the parties agreed to submit their settlement and license agreement to the FTC Bureau of Competition and the DOJ Antitrust Division, reflecting the regulatory scrutiny that attaches to branded-generic pharmaceutical settlements. Each party bears its own costs and attorneys’ fees, a common feature of negotiated resolutions at this stage.
A 208-day resolution is consistent with the early-settlement pattern frequently seen in Hatch-Waxman cases where a license is commercially preferable to protracted litigation through the 30-month stay period. The FTC/DOJ submission requirement under the MMA suggests the agreement may include an authorised-entry date — a commercially sensitive term that governs when Deva may launch its generic product. The specific entry date and royalty or licensing terms are not disclosed in the public record, leaving the full competitive impact of this settlement unresolved from publicly available information alone.
Filing to Dismissed without Prejudice in 208 days
208 days — faster than the median Hatch-Waxman district court resolution
Settlement reached: what the without-prejudice dismissal means for both parties
Dismissed without prejudice under a settlement and license agreement
A dismissal without prejudice means the court has not adjudicated the merits of any patent claim. The suit is terminated at the parties’ mutual request, but Astellas retains the legal right to refile against Deva on these patents if the Settlement and License Agreement is later declared null and void — for instance, following FTC or DOJ antitrust review. The stipulation expressly requests the court retain jurisdiction for this purpose.
No merits rulingLicense agreement signals authorised generic entry — terms undisclosed
The parties describe a ‘Settlement and License Agreement,’ which in Hatch-Waxman practice typically grants the generic manufacturer a future authorised entry date in exchange for ceasing its Paragraph IV challenge. The specific entry date, royalty structure, and any market exclusivity provisions are not disclosed in the public record. The MMA filing obligation to the FTC and DOJ indicates the agreement constitutes a ‘reverse payment’ or related settlement subject to antitrust scrutiny.
License granted — terms confidentialMMA submission to FTC and DOJ is mandatory — antitrust review pending
Under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, any settlement between a branded and generic pharmaceutical company resolving a Paragraph IV patent dispute must be reported to antitrust regulators. The parties have committed to submit the agreement ‘as soon as practicable.’ Regulatory review could, in theory, render the settlement null and void, triggering the court’s retained jurisdiction and potentially reopening litigation.
FTC/DOJ review requiredMyrbetriq® patent portfolio intact — generic launch date controls market risk
With all four patents-in-suit surviving unchallenged on the merits, Astellas’s mirabegron IP position is not weakened by this case. The commercially critical question — when Deva may lawfully enter the market — is embedded in the confidential license. Competitors and payers monitoring Myrbetriq® biosimilar and generic entry timelines should track any FTC or DOJ disclosures related to this settlement for market-entry signals.
Patent position preservedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Astellas Pharma, Inc. | Company | Global pharmaceutical company — holder of four mirabegron extended-release tablet patentsSearch in Eureka ↗ |
| Defendant | Deva Holding A/S | Individual | Generic pharmaceutical company developing mirabegron extended-release tablets (25 mg, 50 mg)Search in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Andrew Lee | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Annie On-Yee Chan | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Ashley Ross | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Bryan S. Hales | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Diva Hollis | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | James F. Hurst | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jeanna M. Wacker | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Michael DelRossi | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Simon D. Roberts | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Tera Stone | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Yun Zhang | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing Astellas Pharma, Inc.Search in Eureka ↗ |
| Defendant counsel | Brent A. Batzer | Attorney | Counsel for Deva Holding A/SSearch in Eureka ↗ |
| Defendant counsel | Dominick T. Gattuso | Attorney | Counsel for Deva Holding A/SSearch in Eureka ↗ |
| Defendant counsel | Shashank S. Upadhye | Attorney | Counsel for Deva Holding A/SSearch in Eureka ↗ |
| Defendant counsel | Yixin H. Tang | Attorney | Counsel for Deva Holding A/SSearch in Eureka ↗ |
| Defendant law firm | Heyman Enerio Gattuso & Hirzel, LLP | Law Firm | Representing Deva Holding A/SSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation confirms that all four patents-in-suit — the ‘780, ‘451, ‘409, and ‘189 patents — were resolved through a negotiated Settlement and License Agreement rather than any merits adjudication. The dismissal without prejudice means no court has ruled on validity, infringement, or enforceability. The court’s express retention of jurisdiction in the event the FTC or DOJ voids the agreement is an unusual but standard MMA safeguard, and suggests the parties anticipated potential regulatory pushback. No adverse finding attaches to either party’s patent or product positions.
US10842780, US11707451, US12059409, US12097189 — Mirabegron Extended-Release Tablets
The four patents-in-suit cover mirabegron extended-release oral tablet formulations in 25 mg and 50 mg dosages, commercialised by Astellas as Myrbetriq® — a beta-3 adrenergic receptor agonist approved for overactive bladder. The portfolio spans applications filed across multiple years (US15/432854 through to US18/613281), reflecting a continuation strategy designed to capture evolving claim scope around the formulation’s release-rate technology, excipient composition, and therapeutic dosing methods.
Mirabegron is a commercially significant asset in the overactive bladder market, where Myrbetriq® competes with antimuscarinics and newer agents. A four-patent portfolio asserted against a single ANDA filer — covering overlapping formulation and method claims — suggests Astellas has constructed an exclusivity thicket consistent with strategies used to maximise the litigation burden on generic entrants and extend effective market exclusivity beyond any single patent’s expiry. Competitors developing mirabegron generics or combination products should map freedom-to-operate against all four patents.
Should you run an FTO against the Myrbetriq® mirabegron patent portfolio?
Any pharmaceutical company, contract manufacturer, or formulation team developing mirabegron extended-release tablets — or any beta-3 adrenergic agonist tablet with comparable release profiles — should conduct a freedom-to-operate analysis against all four Astellas patents. The portfolio’s multi-continuation structure means that claim scope may extend beyond the specific excipient ratios in Myrbetriq® to cover related extended-release mechanisms. Deva’s experience — and the absence of any invalidity ruling — means no prior art escape route has been judicially confirmed.
PatSnap Eureka’s FTO Search Agent can map your formulation parameters against the claims of US10842780, US11707451, US12059409, and US12097189 simultaneously, identifying claim overlap, prosecution history estoppel, and relevant prior art in the extended-release oral solid dosage form space. Eureka surfaces continuation relationships and related foreign counterparts, giving your IP and R&D teams a comprehensive clearance picture before an ANDA filing or product launch decision.
Run a freedom-to-operate analysis on US11707451B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman Mirabegron and Overactive Bladder Patent Cases
Explore related Hatch-Waxman patent infringement cases involving mirabegron formulations and extended-release oral tablets litigated in Delaware District Court.
What this case signals for the Hatch-Waxman mirabegron IP landscape
A licensed settlement over four mirabegron patents reinforces Astellas’s exclusivity position and raises the bar for future generic challengers in this space.
Four-patent assertion signals a layered Myrbetriq® exclusivity strategy
Astellas asserted four patents spanning multiple application filing dates — US10842780 (App. US15/432854), US11707451 (App. US17/114890), US12059409, and US12097189 — suggesting a portfolio approach designed to extend exclusivity across formulation, method, and composition claims. Generic entrants must clear all four patents, raising the litigation cost and settlement leverage for Astellas.
Early settlement preserves the 30-month stay clock as a negotiating tool
Resolving within 208 days — well inside the 30-month Hatch-Waxman stay period — means Astellas avoided full discovery exposure on all four patents. For branded pharma companies, early settlement retains negotiating leverage over entry dates without risking adverse claim construction rulings that could weaken the portfolio against subsequent ANDA filers.
Astellas v Deva — key questions answered
Astellas asserted four patents: US10842780B2, US11707451B2, US12059409B1, and US12097189B1. All four cover mirabegron extended-release oral tablet formulations in 25 mg and 50 mg dosages, corresponding to Astellas’s Myrbetriq® product. The case was filed in Delaware District Court on 28 February 2025.
The case was resolved through a Settlement and License Agreement. The parties filed a joint stipulation requesting dismissal of all claims without prejudice on 24 September 2025, 208 days after filing. Each party agreed to bear its own costs and attorneys’ fees. No merits ruling was issued on any of the four patents-in-suit.
Under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA), any settlement between a branded and a generic pharmaceutical company resolving a Paragraph IV patent dispute must be reported to the FTC Bureau of Competition and the DOJ Antitrust Division. This requirement applies because such settlements can raise antitrust concerns, particularly where a value transfer from the brand to the generic is involved.
Dismissal without prejudice means no court has ruled on the validity, infringement, or enforceability of any of the four Astellas mirabegron patents. Astellas retains the right to refile against Deva if the settlement agreement is voided by antitrust regulators. All four patents retain their full presumption of validity, preserving Astellas’s IP position against subsequent generic challengers.
The dispute centred on Deva’s proposed generic 25 mg and 50 mg mirabegron extended-release tablets, which Astellas alleged would infringe its Myrbetriq® patent portfolio. Myrbetriq® (mirabegron) is a beta-3 adrenergic receptor agonist approved for the treatment of overactive bladder. The four asserted patents cover the extended-release formulation technology underlying the branded product.
PatSnap Eureka searches patents and litigation data to answer instantly.